Top-News

Abliva News

Aktie
WKN:  A0X93Z ISIN:  SE0002575340 US-Symbol:  NEVPF
0,0082 €
-0,001 €
-10,87%
03.05.24 13:54:20
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
3,11 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website

Abliva News

26.06.20 - DGAP
Edison Investment Research Limited: Edison issues update on Abliva (NVP)
Edison Investment Research Limited Edison Investment Research Limited: Edison issues update on Abliva (NVP) 26-Jun-2020 / 12:41 GMT/BST London, UK, 26 June 2020 ...
19.02.20 - PR Newswire
NeuroVive Pharmaceutical AB Year End Report January - December 2019
NeuroVive Pharmaceutical AB Year End Report January - December 2019 PR Newswire
19.02.20 - PR Newswire
NeuroVive Pharmaceutical AB Year End Report January - December 2019
NeuroVive Pharmaceutical AB Year End Report January - December 2019 PR Newswire
20.12.19 - PR Newswire
NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study
NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study PR Newswire
20.12.19 - PR Newswire
NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study
NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study PR Newswire
16.12.19 - PR Newswire
NeuroVive Announces Settlement in Dispute With CicloMulsion AG
NeuroVive Announces Settlement in Dispute With CicloMulsion AG PR Newswire
16.12.19 - PR Newswire
NeuroVive Announces Settlement in Dispute With CicloMulsion AG
NeuroVive Announces Settlement in Dispute With CicloMulsion AG PR Newswire
20.11.19 - PR Newswire
NeuroVive Pharmaceutical AB Interim Report January - September 2019
NeuroVive Pharmaceutical AB Interim Report January - September 2019 PR Newswire
20.11.19 - PR Newswire
NeuroVive Pharmaceutical AB Interim Report January - September 2019
NeuroVive Pharmaceutical AB Interim Report January - September 2019 Continued Progress in KL1333 PR Newswire
21.08.19 - PR Newswire
NeuroVive Pharmaceutical AB Interim Report January - June 2019
NeuroVive Pharmaceutical AB Interim Report January - June 2019 PR Newswire
21.08.19 - PR Newswire
NeuroVive Pharmaceutical AB Interim Report January - June 2019
NeuroVive Pharmaceutical AB Interim Report January - June 2019 Focus on genetic mitochondrial diseases PR Newswire
20.08.19 - PR Newswire
Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019
Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019 PR Newswire
27.07.19 - PR Newswire
NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation
NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation PR Newswire
27.07.19 - PR Newswire
NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation
NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation PR Newswire
04.07.19 - PR Newswire
NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study
NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study PR Newswire
04.07.19 - PR Newswire
NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study
NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study PR Newswire
21.05.19 - PR Newswire
NeuroVive Pharmaceutical AB Interim Report January - March 2019
NeuroVive Pharmaceutical AB Interim Report January - March 2019 First subjects enrolled in the KL1333 study PR Newswire
10.05.19 - PR Newswire
NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA
NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA PR Newswire
10.05.19 - PR Newswire
NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA
NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA PR Newswire
25.03.19 - PR Newswire
NeuroVive Pharmaceutical AB Publishes 2018 Annual Report
NeuroVive Pharmaceutical AB Publishes 2018 Annual Report PR Newswire

Newssuche

Videos

newspaper
03.05.24 -13,45%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »